Compare MATV & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MATV | ARVN |
|---|---|---|
| Founded | 1995 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Paper | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 665.6M | 600.2M |
| IPO Year | 1996 | 2018 |
| Metric | MATV | ARVN |
|---|---|---|
| Price | $11.75 | $6.84 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 15 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 457.4K | ★ 859.5K |
| Earning Date | 11-04-2026 | 11-03-2026 |
| Dividend Yield | ★ 3.33% | N/A |
| EPS Growth | N/A | ★ 58.84 |
| EPS | N/A | ★ 0.88 |
| Revenue | N/A | ★ $262,600,000.00 |
| Revenue This Year | $0.71 | $5.67 |
| Revenue Next Year | $3.32 | N/A |
| P/E Ratio | ★ N/A | $7.78 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.07 | $6.33 |
| 52 Week High | $15.48 | $14.22 |
| Indicator | MATV | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 49.21 | 41.87 |
| Support Level | $11.43 | $6.74 |
| Resistance Level | $12.59 | $7.85 |
| Average True Range (ATR) | 0.59 | 0.47 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 41.74 | 27.06 |
Mativ Holdings Inc is a leader in specialty materials, solving its customers' complex challenges by engineering bold, inventive solutions that connect, protect, and purify the world. The company operates in two segments, namely Filtration & advanced Materials, focused on filtration media and components, developed films, coating and converting solutions, and extruded mesh products, and (2) Sustainable & Adhesive Solutions (SAS), focused on tapes, labels, liners, specialty paper, packaging, and healthcare solutions.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.